Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $59.60

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $61.33.

JANX has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $53.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 11th. BTIG Research initiated coverage on Janux Therapeutics in a research note on Thursday, March 21st. They set a “buy” rating and a $62.00 price target for the company. Bank of America upped their price target on Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, March 13th. Cantor Fitzgerald initiated coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price target for the company. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th.

Institutional Trading of Janux Therapeutics

Several large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Janux Therapeutics by 2.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 47,690 shares of the company’s stock valued at $628,000 after acquiring an additional 1,127 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 4.5% in the first quarter. Rhumbline Advisers now owns 26,849 shares of the company’s stock valued at $325,000 after acquiring an additional 1,158 shares in the last quarter. State of Wisconsin Investment Board lifted its position in shares of Janux Therapeutics by 14.3% in the second quarter. State of Wisconsin Investment Board now owns 13,202 shares of the company’s stock valued at $157,000 after acquiring an additional 1,647 shares in the last quarter. American International Group Inc. lifted its position in shares of Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company’s stock valued at $126,000 after acquiring an additional 1,782 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Janux Therapeutics by 149.4% in the first quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock valued at $40,000 after acquiring an additional 2,003 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 5.1 %

JANX opened at $47.96 on Monday. Janux Therapeutics has a 52 week low of $5.65 and a 52 week high of $58.69. The business’s 50 day moving average is $33.62 and its two-hundred day moving average is $17.61. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -35.79 and a beta of 4.18.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. The company had revenue of $2.46 million during the quarter, compared to analysts’ expectations of $0.98 million. Equities analysts expect that Janux Therapeutics will post -1.41 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.